PADCEV vs TECENTRIQ

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 22, 2026·How we rate

Possible drug interaction. PADCEV and TECENTRIQ are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	PADCEV	TECENTRIQ
Rating	72/100	70/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	ENFORTUMAB VEDOTIN-EJFV	ATEZOLIZUMAB
Manufacturer	Astellas	Genentech Inc
Dosage forms	Injectable	Injectable
Drug class	—	—
Boxed warning	Boxed warning	None
Treats	Urinary Bladder Neoplasms	Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Hepatocellular Carcinoma

padcev tecentriq

Rating

72/100

70/100

Pharmacy pays

—

Type

Active ingredient

ENFORTUMAB VEDOTIN-EJFV

ATEZOLIZUMAB

Manufacturer

Astellas

Genentech Inc

Dosage forms

Injectable

Drug class

—

Boxed warning

None

Treats

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Hepatocellular Carcinoma

Frequently asked questions

Which is better-rated, Padcev or Tecentriq?

By our independent rating, Padcev scores higher — 3.6 vs 3.5 out of 5 for Tecentriq. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Padcev and Tecentriq?

Padcev contains Enfortumab Vedotin-Ejfv, while Tecentriq contains Atezolizumab — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.